TY - JOUR
T1 - Pharmacotherapy of hormone refractory prostate cancer
T2 - New developments and challenges
AU - Rosenbaum, Eli
AU - Carducci, Michael A.
N1 - Funding Information:
Funding for studies discussed in this article was provided by Abbott Laboratories and Aventis. Dr Carducci is a paid consultant for Abbott Laboratories. He is on the Aventis Speakers Bureau and receives research funding from Aventis. The terms of this arrangement are being managed by the Johns Hopkins University in accordance with its conflict of interest policies.
PY - 2003/6/1
Y1 - 2003/6/1
N2 - Hormone refractory prostate cancer (HRPC) remains a challenge in the management of prostate cancer patients. With the widespread use of PSA (prostate specific antigen), recurrent disease after local treatment for localised prostate cancer is usually diagnosed long before evidence of metastatic disease. In many cases, hormonal manipulations are started at the time of biochemical relapse and therefore, patients become 'hormone refractory' earlier in the course of their disease, frequently with a good performance status, often with no evidence of metastatic disease, and they still face a considerably long life expectancy. Despite these changes, the need for more options in the treatment of HRPC is obvious. The pharmacological treatments that are in use and those that are under investigation for this group of patients will be discussed and include: cytotoxic agents including the microtubule inhibitors, alone and in combination with other conventional or experimental therapies such as calcitriol or thalidomide; treatment with epothilone analogues; endothelin receptor antagonists; palliative therapy with bisphosphonates, bone-targeted radiopharmaceuticals and other developing treatments such as vaccines, gene therapies and monoclonal antibodies.
AB - Hormone refractory prostate cancer (HRPC) remains a challenge in the management of prostate cancer patients. With the widespread use of PSA (prostate specific antigen), recurrent disease after local treatment for localised prostate cancer is usually diagnosed long before evidence of metastatic disease. In many cases, hormonal manipulations are started at the time of biochemical relapse and therefore, patients become 'hormone refractory' earlier in the course of their disease, frequently with a good performance status, often with no evidence of metastatic disease, and they still face a considerably long life expectancy. Despite these changes, the need for more options in the treatment of HRPC is obvious. The pharmacological treatments that are in use and those that are under investigation for this group of patients will be discussed and include: cytotoxic agents including the microtubule inhibitors, alone and in combination with other conventional or experimental therapies such as calcitriol or thalidomide; treatment with epothilone analogues; endothelin receptor antagonists; palliative therapy with bisphosphonates, bone-targeted radiopharmaceuticals and other developing treatments such as vaccines, gene therapies and monoclonal antibodies.
KW - Chemotherapy
KW - Docetaxel
KW - Endothelin receptor
KW - Prostate cancer
KW - Vaccines
UR - http://www.scopus.com/inward/record.url?scp=0038347227&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0038347227&partnerID=8YFLogxK
U2 - 10.1517/14656566.4.6.875
DO - 10.1517/14656566.4.6.875
M3 - Review article
C2 - 12783585
AN - SCOPUS:0038347227
SN - 1465-6566
VL - 4
SP - 875
EP - 887
JO - Expert opinion on pharmacotherapy
JF - Expert opinion on pharmacotherapy
IS - 6
ER -